Nisa Investment Advisors’s Taysha Gene Therapies TSHA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$22.8K Sell
5,107
-405
-7% -$1.88K ﹤0.01% 1959
2025
Q4
$30.3K Sell
5,512
-360
-6% -$1.75K ﹤0.01% 1787
2025
Q3
$19.2K Buy
5,872
+2,125
+57% +$6.02K ﹤0.01% 2023
2025
Q2
$8.66K Sell
3,747
-483
-11% -$1.05K ﹤0.01% 2325
2025
Q1
$5.88K Buy
4,230
+3,423
+424% +$5.73K ﹤0.01% 2214
2024
Q4
$1.4K Buy
807
+303
+60% +$629 ﹤0.01% 2590
2024
Q3
$1.01K Buy
+504
New +$1.11K ﹤0.01% 2574
2022
Q2
Sell
-19,800
Closed -$129K 2511
2022
Q1
$129K Buy
+19,800
New +$148K ﹤0.01% 1537

Other funds holding TSHA

Nisa Investment Advisors's TSHA Position: Q1 2026 in Review

Nisa Investment Advisors reduced its Taysha Gene Therapies (TSHA) stake by 7.3% in Q1 2026, selling an estimated $1.88K and leaving 5,107 shares worth $22.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1959.

Nisa Investment Advisors first reported a position in TSHA in Q1 2022 and has held it in 8 quarters since. The position peaked at $129K in Q1 2022. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Nisa Investment Advisors held 5,107 shares of Taysha Gene Therapies worth $22.8K as of Q1 2026.
  • Nisa Investment Advisors sold 405 Taysha Gene Therapies shares in Q1 2026, an estimated $1.88K.
  • Taysha Gene Therapies made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q1 2026, its #1959 holding.
  • Nisa Investment Advisors first reported a position in Taysha Gene Therapies in Q1 2022 and has held it in 8 quarters since.
  • Nisa Investment Advisors's Taysha Gene Therapies position peaked at $129K in Q1 2022.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Nisa Investment Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.